{
 "context": "The following article called 'Quintiles Named 2015 Frost & Sullivan Asia Pacific CRO Company of the Year' was published on 2015-10-16. The body of the article is as follows:\n    \nFriday, October 16, 2015 4:12PM IST (10:42AM GMT) Quintiles Named 2015 Frost & Sullivan Asia Pacific CRO Company of the Year F&S research places Quintiles as \u2018the clear market leader\u2019 among Asia Pacific CROs Singapore Citing Quintiles \u2019 innovation, customer service and growth, Frost & Sullivan has named Quintiles as its Asia Pacific Contract Research Organization Company of the Year. \u201cQuintiles is the clear market leader in the Asia Pacific CRO landscape,\u201d said Rhenu Bhuller, Partner, Healthcare, Frost & Sullivan. \u201cAsia Pacific is a strong focus area for multinational CROs and we evaluated the top five on two key factors \u2013\u2018visionary innovation and performance\u2019 and \u2018customer impact\u2019. Quintiles scored highly in all criteria, and particularly so in \u2018pioneering best practices\u2019 and \u2018addressing biopharma\u2019s unmet needs\u2019. \u201cFor example, Quintiles launched a dedicated medical devices unit in Asia Pacific in 2015 that leverages the expertise of Novella Clinical , a Quintiles company. It also introduced a custom-tailored set of solutions for Asia Pacific emerging biopharma. Both of these are fast-growing market sectors and ones in which government and industry are trying to build capabilities. Quintiles is well-positioned to support this growth.\u201d Frost & Sullivan, a leading business research and consulting firm, also cited Quintiles\u2019 continued expansion of services in Asia Pacific, particularly in Greater China, Japan and South Korea; and its use of innovative technologies to improve efficiency and quality. Quintiles President and Head of Asia Pacific Anand Tharmaratnam said: \u201cThis honor belongs to our 10,000 plus employees across Asia Pacific who work every day to improve our customers\u2019 probability of success. I believe Asia is entering a new era \u2013 one marked by global leadership in biopharma R&D and by diffusion of Asian innovation to global markets. \u201cWith 60 percent of the world\u2019s population, there is tremendous need in Asia Pacific for medicines that will deliver better value and improve patient outcomes. We\u2019re very proud to receive this honor in recognition of our efforts to help achieve that.\u201d Quintiles opened its first Asia Pacific office (Tokyo) in 1993 and this year is celebrating the 20th anniversary of Quintiles Singapore, its Asia Pacific regional headquarters. With a database of more than 17,000 investigator sites or hospitals across Asia Pacific, Quintiles has conducted more than 1,100 studies covering a wide range of therapeutic areas \u2013 including cardiovascular disease, oncology, neurology and infectious diseases \u2013 involving almost 250,000 patients since 2000. Over the last 12 months Quintiles has won the Vaccine Industry Excellence Best CRO Award; received SCRIP Awards Best CRO honors; and been named to the InformationWeek Elite 100. Earlier this year Dr. Tharmaratnam was named \u201cBest Life Science Asian Male Executive of the Year\u201d at the BioPharma Asia Industry Awards. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world\u2019s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE\u2019s list of the \u201cWorld\u2019s Most Admired Companies.\u201d To learn more, visit www.quintiles.com .\n\n    The day before the article was published, the stock price of Acadia Healthcare Company, Inc. was 63.09000015258789 and the day after the article was published, the stock price of Acadia Healthcare Company, Inc. was ",
 "expected": "64.5",
 "date": "2015-10-16",
 "ticker": "ACHC",
 "company": "Acadia Healthcare Company, Inc."
}